{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:58:17Z","timestamp":1740142697178,"version":"3.37.3"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.65.10.1231","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:33:32Z","timestamp":1573068812000},"page":"1231-1239","source":"Crossref","is-referenced-by-count":4,"title":["Peyronie\u2019s disease: clinical treatment"],"prefix":"10.1590","volume":"65","author":[{"given":"Giuliano","family":"Aita","sequence":"first","affiliation":[{"name":"Sociedade Brasileira de Urologia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Teod\u00f3sio da","family":"Ros","sequence":"additional","affiliation":[{"name":"Sociedade Brasileira de Urologia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Silvinato","sequence":"additional","affiliation":[{"name":"Sociedade Brasileira de Urologia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-5207","authenticated-orcid":false,"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Programa Diretrizes da Associa\u00e7\u00e3o M\u00e9dica Brasileira,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","article-title":"Inflammatory mechanisms and oxidative stress in Peyronie\u2019s disease: therapeutic \u201crationale\u201d and related emerging treatment strategies","volume":"11","author":"Paulis G","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis K","year":"2012","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ijir.2011.18","article-title":"The association between Peyronie\u2019s and Dupuytren\u2019s disease","volume":"23","author":"Nugteren HM","year":"2011","journal-title":"Int J Impot Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1743-6109.2011.02502.x","article-title":"Peyronie\u2019s disease in teenagers","volume":"9","author":"Tal R","year":"2012","journal-title":"J Sex Med"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.4103\/2156-7514.103053","article-title":"US Imaging in Peyronie\u2019s Disease","volume":"2","author":"Kalokairinou K","year":"2012","journal-title":"J Clin Imaging Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2011.45","article-title":"Review of non-surgical treatment options for Peyronie\u2019s disease","volume":"24","author":"Larsen SM","year":"2012","journal-title":"Int J Impot Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/14656566.2011.544252","article-title":"Current status and new developments in Peyronie\u2019s disease: medical, minimally invasive, and surgical treatment options","volume":"12","author":"Gur S","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1743-6109.2007.00537.x","article-title":"A Survey of primary-care physicians and urologists regarding Peyronie\u2019s disease","volume":"4","author":"LaRochelle JC","year":"2007","journal-title":"J Sex Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs. tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report","volume":"88","author":"Biagiotti G","year":"2001","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken C","year":"1999","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie\u2019s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-Carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park TY","year":"2016","journal-title":"World J Mens Health"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium para-aminobenzoate (POTABA) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner W","year":"2005","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo-controlled, randomized study","volume":"178","author":"Safarinejad MR","year":"2007","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study","volume":"67","author":"Inal T","year":"2006","journal-title":"Urology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis G","year":"2013","journal-title":"Andrology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/01485010500302014","article-title":"Does smoking change the efficacy of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie\u2019s disease?","volume":"52","author":"Cakan M","year":"2006","journal-title":"Arch Androl"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown BG","year":"2001","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard M","year":"2013","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz LI","year":"2015","journal-title":"BJU Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie\u2019s disease (PD)","volume":"116","author":"Carson 3rd CC","year":"2015","journal-title":"BJU Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie\u2019s Disease","volume":"14","author":"Nguyen HMT","year":"2017","journal-title":"J Sex Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom WJ","year":"2006","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie\u2019s disease","volume":"2","author":"Kendirci M","year":"2005","journal-title":"J Sex Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","article-title":"Outcomes of intralesional interferon-\u03b12B for the treatment of Peyronie disease","volume":"190","author":"Trost LW","year":"2013","journal-title":"J Urol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","article-title":"Intralesional Injection of Interferon-\u03b12b Improves Penile Curvature in Men with Peyronie\u2019s Disease Independent of Plaque Location","volume":"194","author":"Stewart CA","year":"2015","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study","volume":"51","author":"Rehman J","year":"1998","journal-title":"Urology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi M","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie\u2019s disease","volume":"168","author":"Levine LA","year":"2002","journal-title":"J Urol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie\u2019s disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla V","year":"2017","journal-title":"Andrology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ijir.2015.22","article-title":"Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study","volume":"28","author":"Twidwell J","year":"2016","journal-title":"Int J Impot Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","article-title":"A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease","volume":"171","author":"Di Stasi SM","year":"2004","journal-title":"J Urol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield JM","year":"2007","journal-title":"J Urol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-016-1834-2","article-title":"Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie\u2019s disease, erectile dysfunction and chronic pelvic pain","volume":"35","author":"Fojecki GL","year":"2017","journal-title":"World J Urol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2016.24","article-title":"A meta-analysis of extracorporeal shock wave therapy for Peyronie\u2019s disease","volume":"28","author":"Gao L","year":"2016","journal-title":"Int J Impot Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-5347(17)66945-3","article-title":"Peyronie\u2019s disease: a study of its natural history and treatment with orthovoltage radiotherapy","volume":"114","author":"Furlow WL","year":"1975","journal-title":"J Urol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"1996","journal-title":"Control Clin Trials"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force","volume":"129","author":"Guyatt G","year":"2006","journal-title":"Chest"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","article-title":"AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews","volume":"62","author":"Shea BJ","year":"2009","journal-title":"J Clin Epidemiol"},{"series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells G","key":"ref39"},{"series-title":"Oxford Centre for Evidence Based Medicine","key":"ref40"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v65n10\/1806-9282-ramb-65-10-1231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T20:20:52Z","timestamp":1596226852000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302019001001231&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["S0104-42302019001001231"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.65.10.1231","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"type":"electronic","value":"1806-9282"},{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}